Design Therapeutics Reports Positive RESTORE-FA Data for DT-216P2 in Friedreich Ataxia

Design Therapeutics, Inc. (Nasdaq: DSGN) announced new four-week clinical and biomarker data from its ongoing Phase 1/2 RESTORE-FA trial, evaluating DT-216P2 in patients with Friedreich ataxia, a rare genetic disease that affects coordination, strength, and daily function.

The company said DT-216P2 showed dose-dependent improvements across several clinical measures, along with increases in frataxin, or FXN, mRNA and protein. Frataxin is important because Friedreich ataxia is linked to reduced FXN expression caused by a genetic GAA repeat expansion.

Key Results From the RESTORE-FA Trial

As of May 17, 2026, 16 patients had completed four weeks of weekly intravenous DT-216P2 treatment. Patients were enrolled across four dose groups: 0.1, 0.3, 0.6, and 1 mpk, with four patients in each group.

In the highest-dose group, 1 mpk, patients showed a mean improvement of 6.4 points on the modified Friedreich’s Ataxia Rating Scale, or mFARS. They also showed a 2.7-point improvement in Upright Stability Score after four weeks of treatment.

The company also reported improvements of more than five points on the PROMIS Fatigue Scale, both at the end of treatment and two weeks after the final dose. Design Therapeutics noted that this exceeded the three-point level generally viewed as a minimal important change in fatigue.

Biomarker Data Showed Increased Frataxin Activity

Beyond clinical measures, DT-216P2 also produced encouraging biomarker activity. At the 1 mpk dose, whole-blood FXN mRNA increased by 65% from baseline. Whole-blood FXN-M and FXN-E protein levels rose by 22% to 27% two weeks after the last dose. Muscle FXN mRNA increased by 42%.

These findings are important because DT-216P2 is designed to target the genetic root of Friedreich ataxia by increasing endogenous frataxin expression. Design Therapeutics describes DT-216P2 as a GeneTAC small-molecule therapeutic candidate that targets the GAA repeat expansion in the FXN gene.

Safety Profile of DT-216P2

Design Therapeutics said DT-216P2 was generally well tolerated. No serious adverse events and no treatment discontinuations were reported. All adverse events were described as mild or moderate.

The company noted mild to moderate temporary ALT elevations in three patients. These were asymptomatic, had no related bilirubin increases, and occurred in patients who were also on background omaveloxolone.

Why This Data Matters

Friedreich ataxia is a serious inherited disease with limited treatment options. It can affect balance, walking, speech, muscle strength, and heart health. Because the condition is linked to reduced frataxin production, a therapy that can raise endogenous FXN levels may represent a meaningful scientific step.

Design Therapeutics said the RESTORE-FA data support moving DT-216P2 toward a registrational development path. The company expects to provide a further update on its development plans in the fourth quarter of 2026.

Investor Reaction

Despite the positive clinical announcement, shares of DSGN were volatile. Investor’s Business Daily reported that the stock initially rose as much as 18% before reversing sharply during trading on May 18, 2026.

Company Background

Design Therapeutics is a clinical-stage biotechnology company based in Carlsbad, California. The company is developing therapies using its GeneTAC platform, which is intended to regulate the expression of specific disease-causing genes. Its pipeline includes DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type 1, and discovery programs in other genetic diseases.

Conclusion

The latest RESTORE-FA data give Design Therapeutics an important early signal for DT-216P2. The treatment showed improvements in clinical measures, fatigue scores, and frataxin-related biomarkers after only four weeks of dosing. While the trial remains early and includes a small number of patients, the results may help shape the next stage of development for a potential new Friedreich ataxia therapy.

#DesignTherapeutics #DSGN #FriedreichAtaxia #DT216P2 #SlimScan #GrowthStocks #CANSLIM